Quality Systems – Page 35

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

Investigating Audit Findings in Pharmacovigilance Systems: Enhancing Benefit-Risk Documentation Pharmaceutical companies often face a multitude of challenges arising from internal audits, particularly regarding the documentation of benefit-risk assessments in Pharmacovigilance…

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

Addressing Audit Findings in Pharmacovigilance Systems During Benefit-Risk Assessments Pharmaceutical companies are increasingly under pressure to ensure that their pharmacovigilance (PV) systems align with regulatory expectations, especially during benefit-risk assessments.…

Packaging compatibility risk during scale-up – how to prevent recall triggers

Mitigating Packaging Compatibility Risks During Scale-Up to Prevent Recalls In pharmaceutical manufacturing, scale-up processes can expose weaknesses in packaging compatibility that might not have been apparent during smaller production runs.…

Case processing backlog during inspection – inspection questioning scenarios

Understanding and Addressing Case Processing Backlogs During Inspections In the highly regulated pharmaceutical environment, inspections can reveal unexpected challenges, including case processing backlogs that may arise during operations. These backlogs…

Extractables and leachables concern during scale-up – CAPA and control strategy

Addressing Extractables and Leachables Issues During Scale-Up: A Comprehensive Investigation Approach During the scale-up of pharmaceutical products, concerns related to extractables and leachables (E&L) can significantly impact product quality and…

Risk management plan gaps during inspection – preventing repeat PV findings

Addressing Gaps in Risk Management Plans During Inspections to Prevent Recurrent Findings In the highly regulated pharmaceutical environment, maintaining robust risk management plans is critical, especially during inspections conducted by…

Container closure integrity risk during development – how to prevent recall triggers

Assessing and Mitigating Container Closure Integrity Risks During Development In the pharmaceutical industry, ensuring container closure integrity (CCI) is paramount during the development phase to prevent potential product recalls and…

Safety signal escalation delay during post-marketing surveillance – inspection questioning scenarios

Addressing Delays in Safety Signal Escalation During Post-Marketing Surveillance Delays in safety signal escalation during post-marketing surveillance can pose significant regulatory challenges for pharmaceutical companies. Such delays not only hinder…

Tag: Quality Systems

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

Packaging compatibility risk during scale-up – how to prevent recall triggers

Case processing backlog during inspection – inspection questioning scenarios

Extractables and leachables concern during scale-up – CAPA and control strategy

Risk management plan gaps during inspection – preventing repeat PV findings

Container closure integrity risk during development – how to prevent recall triggers

Safety signal escalation delay during post-marketing surveillance – inspection questioning scenarios

Artwork change error during market launch – documentation gaps regulators question

PV system audit finding during signal review – regulatory enforcement risk and mitigation

Stability impact underestimated during market launch – CAPA and control strategy

Risk management plan gaps during post-marketing surveillance – preventing repeat PV findings